Hatem Hachicha is Pfizer's former manager for Tunisia, Libya and French-speaking African countries. He believes Tunisia’s pharmaceutical industry development will be achieved through internationalization and a shift towards biosimilars drugs. Co-founder of SEPHIRE and an active member of the Tunisian healthcare community, he stresses that one of the challenges in Tunisia is to prevent public medicine from falling behind private services despite the fact that Tunisia reserves nearly 7% of its GDP to public health, one of the highest rates in Africa. In addressing this issue, universal access to care and innovative therapies would be guaranteed. He also documents the manner in which the private sector benefits from the development of medical tourism.
All the stakeholders of the health industry in Tunisia know you. Could you detail your career path to our readers?
"The private sector is highly developed and offers services of impeccable quality. Moreover, it is the reason for the medical tourism currently expanding within Tunisia and for which the potential for growth remains strong."
